Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSinclair Pharma Regulatory News (SPH)

  • There is currently no data for SPH

Director/PDMR Shareholding

25 Apr 2014 11:04

RNS Number : 5469F
Sinclair IS Pharma PLC
25 April 2014
 



25 April 2014

Director's Dealing

 

Sinclair IS Pharma plc (SPH.L), ("Sinclair" or the "Group") the international specialty pharma company, was informed on 24 April 2014 that earlier that day Stuart Swanson, a Non-Executive Director, acquired 25,555 ordinary shares in Sinclair at a price of 30.5p per share. Following this purchase Stuart Swanson has a beneficial interest in 4,324,498 ordinary shares representing 0.99% of the Group's issued ordinary share capital. For the avoidance of doubt this holding excludes the 3,125,000 Placing Shares that Stuart Swanson is subscribing for as part of the Placing announced on 15 April 2014 which is due to complete on 2 May 2014.

For further information, please contact:

Sinclair IS Pharma plc Tel: +44 (0) 20 7467 6920

Chris Spooner

Alan Olby

Robert Taylor

 

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Clare Terlouw

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFIISVIEFIS
Date   Source Headline
28th Mar 20177:15 amRNSHardman Research: Much more streamlined
27th Mar 201710:30 amRNSAppointment of Joint Broker
22nd Mar 20175:29 pmRNSHolding(s) in Company
21st Mar 20177:00 amRNSPreliminary Results
21st Mar 20177:00 amRNSSettlement Agreement with Sinclair Pharma plc
17th Jan 20179:27 amRNSHardman Research: Demanding targets exceeded
17th Jan 20177:00 amRNSPre-Close Trading Update
5th Jan 20177:15 amRNSNotification of full year trading update
17th Nov 201610:39 amRNSDirector/PDMR Shareholding
17th Nov 201610:36 amRNSAdditional Listing
8th Nov 20169:08 amRNSHardman Research: Poised for a long term uplift
8th Nov 20167:05 amRNSHardman Research: Poised for a long term uplift
18th Oct 20165:55 pmRNSHolding(s) in Company
13th Oct 20164:46 pmRNSHolding(s) in Company
5th Oct 20167:00 amRNSDirector/PDMR Shareholding
3rd Oct 20163:56 pmRNSHolding(s) in Company
30th Sep 20162:29 pmRNSTotal Voting Rights
29th Sep 20162:24 pmRNSHolding(s) in Company
28th Sep 20162:23 pmRNSAdditional Listing
27th Sep 20164:14 pmRNSDirector/PDMR Shareholding
27th Sep 20164:12 pmRNSDirector/PDMR Shareholding
26th Sep 20165:04 pmRNSAdditional Listing
22nd Sep 20162:02 pmRNSHolding(s) in Company
21st Sep 20167:00 amRNSHalf-year Report
1st Sep 20167:00 amRNSRestructuring Programme and Board Change
22nd Aug 20167:00 amRNSNotice of Results
19th Jul 20167:00 amRNSTrading Statement
2nd Jun 20167:00 amRNSPresenting at Jefferies Healthcare Conference
31st May 20167:00 amRNSDirector Dealing
24th May 20169:52 amRNSPurchase of shares by Chief Financial Officer
23rd May 20167:00 amRNSDirector Dealing
20th May 201611:43 amRNSOption Awards
20th May 201610:16 amRNSDirector Dealings
20th May 20167:00 amRNSUS Collaboration and Positive Trading Update
19th May 20164:35 pmRNSUS Collaboration and Positive Trading Update
19th May 20162:15 pmRNSForm 8.3 - SINCLAIR PHARMA PLC
19th May 201612:50 pmRNSForm 8.3 - Sinclair Pharma PLC
19th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
18th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
18th May 201611:24 amRNSForm 8.3 - Sinclair Pharma plc
17th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
16th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
13th May 20161:35 pmRNSForm 8.3 - Sinclair Pharma plc
12th May 201612:40 pmRNSForm 8.3 - Sinclair Pharma plc
11th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
10th May 20162:13 pmRNSForm 8.3 - SINCLAIR PHARMA PLC
10th May 20161:56 pmRNSForm 8.3 - Sinclair Pharma plc
9th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
6th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
6th May 201611:25 amPRNForm 8.3 - Sinclair Pharma Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.